ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0916

Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis

Fiza Ahmed1, Svetlana Nihtyanova1, Stamatia Chatzinikolaou2, Voon Ong1, Charles Murray2 and Christopher Denton3, 1Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, 2Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, 3University College London, London, United Kingdom

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Scleroderma, Scleroderma, Localized, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk of developing severe GI disease would be helpful for clinical trials and practice.

Previously, we identified demographic factors and serological markers associated with certain gastrointestinal symptoms, in a cohort (n=214) of consecutive SSc patients.  Here, we have validated and extended our work in a second independent cohort.

Methods: SSc patients attending our centre between December 2019 and March 2020 completed the UCLA SCTC GIT 2.0 questionnaire, encompassing various domains of SSc-associated GI disease (reflux, distension/bloating, diarrhoea, soilage, constipation, social functioning and emotional wellbeing). Higher domain scores correspond with greater GI disease severity (domain scores range from 0 to 3). Analysis of associations was undertaken using appropriate non-parametric tests.  Subgroups on basis of antibodies included ACA, ATA, ARA, U3RNP, nRNP, PmScl and other antibodies. Double autoantibodies were present in 10 subjects and those were classified into the group of the more SSc-specific antibody.

Results: 314 patients completed UCLA GIT 2.0. Mean (SD) age was 55.2 (14.5) and 85.7% were female. The mean number of years since SSc onset was 12.9 (10.0). Limited cutaneous SSc was present in 66.6%, and disease overlap syndromes were present in 25.4%. The most common autoantibody was anti-centromere (ACA, 28.0%), followed by anti-topoisomerase (ATA, 24.2%), anti-RNA polymerase III (ARA, 9.9%), Ro (8.9%), anti-PMScl (6.1%) and anti-nRNP (5.7%). The mean (SD) total GIT score was 0.70 (0.58) and 56.4% patients reported moderate-severe symptoms (Table 1). There was a positive correlation between total GIT score and patient visual analogue scale (VAS) self-reported GI disease burden (Spearman’s Rho = 0.68, p < 0.0001). There was no association between GI symptoms and disease subset or duration. Gender was only associated with emotional wellbeing, which was more severely affected in females compared to males (score 0.68 v 0.42, p=0.0339). There were significant differences between the antibody subgroups in terms of GI symptoms (Table 2). Of the SSc-specific antibodies, ARA and ACA appeared to convey increased risk overall and throughout the domains, demonstrating the highest scores. Mean/median total GIT scores and scores for reflux, distension/bloating, constipation, social functioning and emotional wellbeing were highest among ARA+, while scores for diarrhoea and faecal soilage were highest among ACA+ subjects. On the other hand, anti-PmScl+ patients had the lowest scores in most domains, including total GIT 2.0 score.

Conclusion: We have validated our previous results in a second SSc cohort. Higher GIT scores were associated with significantly worse self-reported impact on quality of life. In addition, in this cohort, ARA and ACA positivity appeared to be associated with more severe GI disease. Future studies should explore whether ANA reactivity may identify cases at risk of severe GI manifestations.

Table 1. Distribution of severity of GI symptoms in SSc cohort (n=314), based on total GI score and individual domain scores for patients fully completing the UCLA SCTC GIT 2.0 questionnaire. Total GI score excludes constipation score. Total score and individual domain score frequencies are represented as n (%).

Table 2. Comparison between autoantibody subgroups in terms of GIT symptoms. Comparisons were undertaken using the Kruskal-Wallis test. Cells represent mean/median, Q2-Q3.


Disclosure: F. Ahmed, None; S. Nihtyanova, GlaxoSmithKline, 3; S. Chatzinikolaou, None; V. Ong, None; C. Murray, None; C. Denton, Janssen, 1, GlaxoSmithKline, 1, 2, Bayer, 1, Sanofi, 1, Inventiva, 1, 2, Boehringer Ingelheim, 1, Roche, 1, Bristol-Myers Squibb, 1, CSL Behring, 1, 2, UCB, 1, Leadiant Biosciences, 1, Corbus Pharmaceuticals, 1, Acceleron Pharma, 1, Horizon Therapeutics, 1, Forbius, 1, Servier, 1.

To cite this abstract in AMA style:

Ahmed F, Nihtyanova S, Chatzinikolaou S, Ong V, Murray C, Denton C. Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/validating-autoantibody-associations-and-clinical-impact-of-severe-gastrointestinal-involvement-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validating-autoantibody-associations-and-clinical-impact-of-severe-gastrointestinal-involvement-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology